Mankind Pharma Limited has informed the Exchange that Board of Directors at its meeting held on July 31, 2025, declared Interim Dividend of 1 per equity share.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma's board, at its July 31, 2025 meeting, approved Q1 FY26 results, an interim dividend of ₹1 per share (100% on face value, record date August 8, 2025), and the acquisition of Bharat Serums and Vaccines' (BSV) branded women health Rx portfolio via slump sale. Consolidated revenue from operations grew ~24.5% YoY to ₹3,570.35 crore (vs ₹2,867.85 crore), boosted by BSV consolidation, though profit after tax from continuing operations fell to ₹444.62 crore from ₹538.48 crore due to higher finance and depreciation costs. Standalone revenue rose to ₹2,541.36 crore with PAT at ₹412.76 crore (vs ₹382.46 crore restated). The board also approved raising up to ₹1,000 crore via commercial papers and noted the resignation of CMO Dr. Sanjay Koul. Auditors flagged an emphasis of matter on ongoing income tax proceedings, where the department has disallowed expenses of ~₹1,546.83 crore, which the company is contesting.
Shareholders receive a small interim dividend (₹1/share) as a token payout while the company directs cash toward acquisitions and debt. Strong topline growth from BSV integration is offset by margin compression and a significant tax litigation overhang (₹1,546+ crore in disputed disallowances), which could weigh on sentiment if appeals are unfavorable.